TY - JOUR
T1 - Author Correction
T2 - Effect of ticagrelor and prasugrel on remote myocardial inflammation in patients with acute myocardial infarction with ST-elevation: a CMR T1 and T2 mapping study (The International Journal of Cardiovascular Imaging, (2022), 39, 4, (767-779), 10.1007/s10554-022-02765-y)
AU - Konijnenberg, Lara S. F.
AU - Zugwitz, Daša
AU - Everaars, Henk
AU - van der Hoeven, Nina W.
AU - Demirkiran, Ahmet
AU - Rodwell, Laura
AU - van Leeuwen, Maarten A. H.
AU - van Rossum, Albert C.
AU - el Messaoudi, Saloua
AU - Riksen, Niels P.
AU - van Royen, Niels
AU - Nijveldt, Robin
N1 - Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Nature B.V.
PY - 2023/6
Y1 - 2023/6
N2 - In the original publication of the paper Table 1 is mixed up and the references incorrectly published. The corrected Table 1 and reference is given in this Correction. (Table presented.) Patient characteristics Ticagrelor (n = 29) Prasugrel (n = 31) p-value Age, years 62.2 ± 10.7 61.6 ± 9.5 0.81 Male, n (%) 23 (79.3) 26 (83.9) 0.75 BMI, kg/m2 27.6 ± 3.9 27.0 ± 3.9 0.54 Medical history, n (%) Hypertension 10 (34.5) 5 (16.1) 0.14 Diabetes mellitus 3 (10.3) 2 (6.5) 0.67 Smoking 15 (51.7) 16 (51.6) 0.99 Current 10 (66.7) 11 (68.8) In the past 5 (33.3) 5 (31.3) Hypercholesterolaemia 3 (10.3) 7 (22.6) 0.30 Prior chronic coronary syndrome 2 (6.9) (0) 0.23 Prior PCI 2 (6.9) PCI-related vessel LAD 1 (3.2) LCX 0 (0) RCA 1 (3.2) In-stent restenosis as culprit lesion (0) Family history of CAD 7 (24.1) 12 (38.7) 0.27 Medication at baseline, n (%) Acetylsalicylic acid 3 (10.3) 1 (3.2) 0.35 β-blocker 4 (13.7) 1 (3.2) 0.18 ACE-i 3 (10.3) 0 (0) 0.11 ARB 4 (13.8) 2 (6.5) 0.42 Calcium antagonist 2 (6.9) 3 (9.7) 1.00 Diuretic 5 (17.2) 0 (0) < 0.01 Lipid lowering medication 3 (10.3) 5 (16.1) 0.71 Anti‐inflammatory drugs 3 (10.3) 3 (9.7) 1.00 Coronary angiography Symptom onset to wire crossing time, min 161 [123 – 494] 122 [96 – 240] 0.07 Culprit artery, n (%) 0.87 LAD 7 (24.1) 9 (29.0) LCX 7 (24.1) 8 (25.8) RCA 15 (51.7) 14 (45.2) Medication at hospital discharge, n (%) Acetylsalicylic acid 29 (100) 31 (100) 1.00 β-blocker 26 (89.7) 29 (93.5) 0.67 ACE-i 22 (75.9) 23 (74.2) 1.00 ARB 5 (17.2) 2 (6.5) 0.25 Calcium antagonist 0 (0) 0 (0) 1.00 Diuretic 1 (3.4) 1 (3.2) 1.00 Lipid lowering medication 28 (96.6) 31 (100) 0.48 Anti‐inflammatory drugs 2 (6.9) 2 (6.5) 1.00 Values are presented as mean ± standard deviation, median [IQR] or absolute number (%) and assessed by independent-samples T test, Mann–Whitney U test, or Chi-square test, respectively ACE-i angiotensin converting enzyme inhibitors; ARB angiotensin II receptor blockers; BMI body mass index; CAD coronary artery disease; LAD left anterior descending coronary artery; LCX left circumflex coronary artery; RCA right coronary artery The original article has been corrected.
AB - In the original publication of the paper Table 1 is mixed up and the references incorrectly published. The corrected Table 1 and reference is given in this Correction. (Table presented.) Patient characteristics Ticagrelor (n = 29) Prasugrel (n = 31) p-value Age, years 62.2 ± 10.7 61.6 ± 9.5 0.81 Male, n (%) 23 (79.3) 26 (83.9) 0.75 BMI, kg/m2 27.6 ± 3.9 27.0 ± 3.9 0.54 Medical history, n (%) Hypertension 10 (34.5) 5 (16.1) 0.14 Diabetes mellitus 3 (10.3) 2 (6.5) 0.67 Smoking 15 (51.7) 16 (51.6) 0.99 Current 10 (66.7) 11 (68.8) In the past 5 (33.3) 5 (31.3) Hypercholesterolaemia 3 (10.3) 7 (22.6) 0.30 Prior chronic coronary syndrome 2 (6.9) (0) 0.23 Prior PCI 2 (6.9) PCI-related vessel LAD 1 (3.2) LCX 0 (0) RCA 1 (3.2) In-stent restenosis as culprit lesion (0) Family history of CAD 7 (24.1) 12 (38.7) 0.27 Medication at baseline, n (%) Acetylsalicylic acid 3 (10.3) 1 (3.2) 0.35 β-blocker 4 (13.7) 1 (3.2) 0.18 ACE-i 3 (10.3) 0 (0) 0.11 ARB 4 (13.8) 2 (6.5) 0.42 Calcium antagonist 2 (6.9) 3 (9.7) 1.00 Diuretic 5 (17.2) 0 (0) < 0.01 Lipid lowering medication 3 (10.3) 5 (16.1) 0.71 Anti‐inflammatory drugs 3 (10.3) 3 (9.7) 1.00 Coronary angiography Symptom onset to wire crossing time, min 161 [123 – 494] 122 [96 – 240] 0.07 Culprit artery, n (%) 0.87 LAD 7 (24.1) 9 (29.0) LCX 7 (24.1) 8 (25.8) RCA 15 (51.7) 14 (45.2) Medication at hospital discharge, n (%) Acetylsalicylic acid 29 (100) 31 (100) 1.00 β-blocker 26 (89.7) 29 (93.5) 0.67 ACE-i 22 (75.9) 23 (74.2) 1.00 ARB 5 (17.2) 2 (6.5) 0.25 Calcium antagonist 0 (0) 0 (0) 1.00 Diuretic 1 (3.4) 1 (3.2) 1.00 Lipid lowering medication 28 (96.6) 31 (100) 0.48 Anti‐inflammatory drugs 2 (6.9) 2 (6.5) 1.00 Values are presented as mean ± standard deviation, median [IQR] or absolute number (%) and assessed by independent-samples T test, Mann–Whitney U test, or Chi-square test, respectively ACE-i angiotensin converting enzyme inhibitors; ARB angiotensin II receptor blockers; BMI body mass index; CAD coronary artery disease; LAD left anterior descending coronary artery; LCX left circumflex coronary artery; RCA right coronary artery The original article has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85152267688&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85152267688&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/37038014
U2 - https://doi.org/10.1007/s10554-023-02803-3
DO - https://doi.org/10.1007/s10554-023-02803-3
M3 - Comment/Letter to the editor
C2 - 37038014
SN - 1569-5794
VL - 39
SP - 1167
EP - 1168
JO - international journal of cardiovascular imaging
JF - international journal of cardiovascular imaging
IS - 6
ER -